Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma.
Animals
Apoptosis
Cell Proliferation
Checkpoint Kinase 1
/ antagonists & inhibitors
Drug Combinations
Esophageal Neoplasms
/ drug therapy
Esophageal Squamous Cell Carcinoma
/ drug therapy
Humans
Male
Mice
Mice, Hairless
Mice, SCID
Protein Kinase Inhibitors
/ pharmacology
Pyrrolidines
/ pharmacology
Synthetic Lethal Mutations
Thymine
/ pharmacology
Trifluridine
/ pharmacology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
24
09
2019
revised:
19
12
2019
accepted:
02
04
2020
pubmed:
7
5
2020
medline:
29
4
2021
entrez:
7
5
2020
Statut:
ppublish
Résumé
Esophageal squamous cell carcinoma (ESCC) is a disease characterized by a high mutation rate of the
Identifiants
pubmed: 32371587
pii: 1535-7163.MCT-19-0918
doi: 10.1158/1535-7163.MCT-19-0918
doi:
Substances chimiques
Drug Combinations
0
Protein Kinase Inhibitors
0
Pyrrolidines
0
trifluridine tipiracil drug combination
0
CHEK1 protein, human
EC 2.7.11.1
Checkpoint Kinase 1
EC 2.7.11.1
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1363-1372Informations de copyright
©2020 American Association for Cancer Research.